Anaconda Mining Inc.

Published : June 16th, 2014

Mast Therapeutics Initiates Sub-Study Within Phase 3 EPIC Trial

( 0 vote, 0/5 ) Print article
  Article Comments Comment this article Rating Follow Company  
0
Send
0
comment

Mast Therapeutics Initiates Sub-Study Within Phase 3 EPIC Trial

SAN DIEGO, June 16, 2014 /PRNewswire/ -- Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that, in line with prior guidance, it has initiated patient enrollment in a sub-study within EPIC, its pivotal phase 3 study of MST-188 in sickle cell disease, to investigate and quantify the effect of MST-188 on tissue oxygenation, which will be measured utilizing a non-invasive, FDA-approved device. 

MST-188 has been shown to reduce viscosity and adhesive frictional forces in blood and improve microvascular blood flow.  Improvements in the flow of oxygen-carrying blood to tissues and organs can be expected to improve tissue oxygenation, shorten the duration of vaso-occlusive crisis, and limit tissue damage and end-organ dysfunction and failure. 

Brian M. Culley, Chief Executive Officer, said: "Organ failure, which is the leading cause of premature death in adults with sickle cell disease, is thought to be the consequence of a lifetime of repeated vaso-occlusive events and the resulting ischemia.  We believe that measuring effects on microvascular blood flow and tissue oxygenation during vaso-occlusive crisis will be useful to understanding MST-188's potential to improve long-term outcomes for sickle cell patients where multi-decade, survival trials are impractical.  MST-188 has already demonstrated an ability to improve microvascular blood flow.  Now, this sub-study will demonstrate whether MST-188 also improves tissue oxygenation.  Together, these data will provide insight into the potential for MST-188 to reduce end-organ failure and associated premature death in individuals with sickle cell disease."

About the EPIC Sub-StudyThe sub-study will enroll patients who are concurrently randomized in the EPIC clinical trial and will be conducted at selected EPIC sites in the U.S.  The primary objective is to evaluate the effects of MST-188 on tissue oxygenation in subjects with sickle cell disease who are experiencing a vaso-occlusive crisis.  Tissue oxygenation will be determined using a non-invasive, U.S. Food and Drug Administration (FDA)-approved device. 

About Mast Therapeutics Mast Therapeutics, Inc. is a publicly traded biopharmaceutical company headquartered in San Diego, California.  The Company is leveraging the MAST (Molecular Adhesion and Sealant Technology) platform, derived from over two decades of clinical, nonclinical and manufacturing experience with purified and non-purified poloxamers, to develop MST-188, its lead product candidate, for serious or life-threatening diseases and conditions typically characterized by impaired microvascular blood flow and damaged cell membranes. 

The Company is enrolling subjects in EPIC, a pivotal phase 3 study of MST-188 in sickle cell disease, and in a phase 2, clinical study to evaluate whether MST-188 improves the effectiveness of recombinant tissue plasminogen activator therapy in patients with acute limb ischemia.  The Company also is developing MST-188 in heart failure and expects to announce its clinical development plans in this indication in the second half of 2014.  More information can be found on the Company's web site at www.masttherapeutics.com. (Twitter: @MastThera

Mast Therapeutics™ and the corporate logo are trademarks of Mast Therapeutics, Inc.

Forward Looking StatementsMast Therapeutics cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that are based on the Company's current expectations and assumptions. Such forward-looking statements include, but are not limited to, statements relating to the usefulness of data from the EPIC sub-study, potential clinical benefits of MST-188 in sickle cell disease, and the Company's development of MST-188 in other indications, including heart failure.  Among the factors that could cause or contribute to material differences between the Company's actual results and the expectations indicated by the forward-looking statements are risks and uncertainties that include, but are not limited to: the uncertainty of outcomes in ongoing and future studies of MST-188 and the risk that MST-188 may not demonstrate adequate safety, efficacy or tolerability in one or more such studies, including EPIC; delays in the commencement or completion of clinical studies, including as a result of difficulties in obtaining regulatory agency agreement on clinical development plans or clinical study design, opening trial sites, enrolling study subjects, manufacturing sufficient quantities of clinical trial material, being subject to a "clinical hold," and/or suspension or termination of a clinical study, including due to patient safety concerns or lack of funding; the potential for institutional review boards or the FDA or other regulatory agencies to require additional nonclinical or clinical studies prior to initiation of a phase 2 clinical study of MST-188 in heart failure or other indications; the risk that, even if clinical studies are successful, the FDA or other regulatory agencies may determine they are not sufficient to support a new drug application; the potential that, even if clinical studies of MST-188 in one indication are successful, clinical studies in another indication may not be successful; the Company's reliance on contract research organizations (CROs), contract manufacturing organizations (CMOs), and other third parties to assist in the conduct of important aspects of development of MST-188, including clinical studies, manufacturing, and regulatory activities, and that such third parties may fail to perform as expected; the Company's ability to obtain additional funding on a timely basis or on acceptable terms, or at all; the potential for the Company to delay, reduce or discontinue current and/or planned development activities, including clinical studies, partner its product candidates at inopportune times or pursue less expensive but higher-risk and/or lower return development paths if it is unable to raise sufficient additional capital as needed; the risk that, even if the Company successfully develops a product candidate in one or more indications, it may not realize commercial success with its products and may never generate revenue sufficient to achieve profitability; the risk that the Company is not able to adequately protect its intellectual property rights relating to the MAST platform and MST-188 or AIR001 and prevent competitors from duplicating or developing equivalent versions of its product candidates; and other risks and uncertainties more fully described in the Company's press releases and periodic filings with the Securities and Exchange Commission. The Company's public filings with the Securities and Exchange Commission are available at www.sec.gov.

You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date when made. Mast Therapeutics does not intend to revise or update any forward-looking statement set forth in this press release to reflect events or circumstances arising after the date hereof, except as may be required by law.

Logo - http://photos.prnewswire.com/prnh/20120612/LA22456LOGO-a

Read the rest of the article at finance.yahoo.com

Anaconda Mining Inc.

EXPLORATION STAGE
CODE : ANX.TO
ISIN : CA03240P1080
Follow and Invest
Add to watch list Add to your portfolio Add or edit a note
Add Alert Add to Watchlists Add to Portfolio Add Note
ProfileMarket
Indicators
VALUE :
Projects & res.
Press
releases
Annual
report
RISK :
Asset profile
Contact Cpy

Anaconda Min. is a gold development stage company based in Canada.

Anaconda Min. holds various exploration projects in Canada and in Chile.

Its main exploration properties are BORTHWICK LAKE, LINGMAN LAKE and DAMOTI in Canada and SAN GABRIEL FE and HORSE MOUNTAIN - ANACONDA GOLD in Chile.

Anaconda Min. is listed in Canada, in Germany and in United States of America. Its market capitalisation is CA$ 146.5 millions as of today (US$ 114.3 millions, € 100.8 millions).

Its stock quote reached its highest recent level on February 09, 2012 at CA$ 2.01, and its lowest recent point on December 24, 2015 at CA$ 0.04.

Anaconda Min. has 209 330 000 shares outstanding.

Your feedback is appreciated, please leave a comment or rate this article.
Rate : Average note :0 (0 vote) View Top rated
 
Financings of Anaconda Mining Inc.
6/3/2013Makes $1,754,580 Final Payment on Convertible Loan and Deben...
5/6/2013Announces Warrant Exercise
8/15/2011announces extension of Series III Debentures and propose...
4/11/2011ANNOUNCES EXTENSION OF COMMON SHARE PURCHASE WARRANTS
Nominations of Anaconda Mining Inc.
7/7/2015Kevin Bullock Joins Board of Directors of Anaconda Mining
11/20/2014Announces Election of Directors
10/10/2013Tim Casgrain Joins Board of Directors of Anaconda Mining
Project news of Anaconda Mining Inc.
1/25/2016Anaconda Mining drills 2.68 g/t Au over 15.9 metres and 2.11...
12/17/2015Anaconda Mining reports 17.76 g/t gold over 11 metres and 4....
2/26/2015Anaconda Mining maximizing Pine Cove deposit potential throu...
12/23/2014Anaconda Mining commences new drilling program on the Pine C...
12/16/2014Anaconda Mining reports 10.52 g/t gold over 3.5 metres, 8.13...
11/6/2014Anaconda Mining reports 18.60 g/t gold over 3.5 meters and 4...
6/11/2014Anaconda Mining initiates 2,000-meter diamond drilling progr...
5/19/2011REPORTS RECORD GOLD PRODUCTION AT PINE COVE: 344.2 TROY ...
Corporate news of Anaconda Mining Inc.
1/21/2016Anaconda Mining reports 1.89 g/t gold over 10 metres and ext...
10/19/2015Anaconda frees up nearly $800,000 in restricted cash
10/15/2015Anaconda Mining sells 3,956 ounces and generates $1.5M of EB...
9/17/2015Anaconda's Point Rousse Project Sells Nearly 4,000 Ounces of...
8/27/2015Anaconda Mining sells 15,821 ounces and generates $4.8m of E...
8/13/2015Anaconda Intersects More Near-Surface Mineralization at Nort...
8/4/2015Anaconda Acquires Corkscrew Property; Doubles Land Position ...
7/29/2015Anaconda Mining Comments on Proposed "Take-Under" Bid Announ...
7/29/2015Plantro Venture Group Ltd. intends to make an offer for Anac...
7/29/2015Anaconda Mining Reports 12.83 g/t Gold Over 4.38 Metres and ...
7/29/2015Reports 12.83 g/t Gold Over 4.38 Metres and 8.55 g/t Gold Ov...
6/18/2015Anaconda Mining sets annual production records and sells nea...
4/9/2015sells 4,508 ounces and generates $1.9M of Point Rousse Proje...
4/9/2015Anaconda Mining sells 4,508 ounces and generates $1.9M of Po...
3/19/2015Point Rousse Project has record sales volume of over 4,500 o...
3/19/2015Anaconda's Point Rousse Project has record sales volume of o...
2/27/2015Anaconda Provides a Strategic and Exploration Update on the ...
2/26/2015maximizing Pine Cove deposit potential through recent drilli...
1/9/2015Anaconda Mining Sells 3,431 Ounces and Generates Over $600,0...
1/8/2015Anaconda makes new gold discovery near the Pine Cove mill
12/23/2014commences new drilling program on the Pine Cove deposit
12/15/2014Pine Cove Mine Sells Over 3,400 Ounces of Gold; Generates $4...
12/15/2014Anaconda's Pine Cove Mine Sells Over 3,400 Ounces of Gold; G...
12/3/2014Anaconda Mining makes final payment on Atlantic Canada oppor...
12/3/2014makes final payment on Atlantic Canada opportunities agency ...
11/20/2014Anaconda Mining Announces Election of Directors
11/6/2014reports 18.60 g/t gold over 3.5 meters and 4.94 g/t gold ove...
10/9/2014Anaconda Mining Sells Nearly 4,000 Ounces and Generates Over...
9/18/2014Anaconda's Pine Cove Mine sells over 3,900 ounces of gold; g...
9/15/2014Anaconda Mining initiates drill program on the Stog'er Tight...
9/15/2014initiates drill program on the Stog'er Tight project
8/28/2014Anaconda Mining posts $4.3 million, or $0.02 per share, in n...
6/18/2014Anaconda Mining Intersects Multiple Zones Grading up to 3.17...
6/17/2014Anaconda's Pine Cove Mine sells approximately 3,800 ounces o...
6/16/2014Mast Therapeutics Initiates Sub-Study Within Phase 3 EPIC Tr...
6/11/2014initiates 2,000-meter diamond drilling program at its Deer C...
5/7/2014reports 26.12 g/t over 3.6 meters and 22.74 g/t over 5.0 met...
10/18/2013Announces Date of Annual Meeting
9/16/2013Intersects New Gold Zone at Romeo and Juliet Prospect; Assay...
9/10/2013Receives First Commercial Production Payment of US$1 Million...
8/26/2013to Receive First Commercial Production Payment of US $1 Mill...
7/8/2013Initiates 2,000-Meter Diamond-Drill Program at Pine Cove's R...
6/18/2013Begins Regional Airborne Geophysical Survey of Its Pine Cove...
6/13/2013Pine Cove Mine has Record FY Q4 '13 Sales Volume of Nearly 4...
4/12/2013Generates $856,762, or $0.005 Per Share, in Net Income for F...
4/4/2013Reports Successful Romeo and Juliet Bulk Sample Assay Result...
3/25/2013Intersects 20 Metres of 2.15 g/t Gold in New Western Extensi...
3/19/2013Pine Cove Mine Sells Approximately 3,100 Ounces of Gold in F...
1/14/2013Initiates Diamond Drilling to Test Potential Down-Dip Extens...
1/14/2013Initiates Diamond Drilling to Test Potential Down-Dip Extens...
12/11/2012Options Strategic Property Near Its Pine Cove Mine; Identifi...
10/12/2012generates $1.5 Million in Net Income for FY Q1 2013
10/6/2011Pine Cove Gold Mine Generates Over $1.5 Million in EBITDA Du...
9/14/2011Pine Cove gold mine posts another record quarter; mill recov...
8/25/2011Pine Cove gold mine generates over $500,000 in EBITDA in Jun...
6/27/2011PINE COVE GOLD MINE GENERATES OVER $900,000 IN EBITDA IN APR...
5/2/2011IMPROVES PINE COVE MILL PERFORMANCE; SHIPS RECORD AMOUNT OF ...
Comments closed
 
Latest comment posted for this article
Be the first to comment
Add your comment
TORONTO (ANX.TO)FRANKFURT (GJ2A.F)
0.700-4.11%0.072+0.00%
TORONTO
CA$ 0.700
12/01 15:59 -0.030
-4.11%
Prev close Open
0.730 0.750
Low High
0.700 0.750
Year l/h YTD var.
0.550 -  1.03 14.75%
52 week l/h 52 week var.
0.540 -  1.03 22.81%
Volume 1 month var.
154,028 9.38%
24hGold TrendPower© : -6
Produces
Develops
Explores for Gold
 
 
 
Analyse
Interactive chart Add to compare
Interactive
chart
Print Compare Export
You must be logged in to use the porfolio and watchlists (free)
Top Newsreleases
MOST READ
Annual variation
DateVariationHighLow
202114.75%0.940.53
2020171.11%0.780.10
20192.27%0.360.19
2018120.00%0.560.09
201766.67%0.110.05
 
5 years chart
 
3 months chart
 
3 months volume chart
 
 
Mining Company News
Plymouth Minerals LTDPLH.AX
Plymouth Minerals Intersects Further High Grade Potash in Drilling at Banio Potash Project - Plannin
AU$ 0.12-8.00%Trend Power :
Santos(Ngas-Oil)STO.AX
announces expected non-cash impairment
AU$ 6.20-1.98%Trend Power :
Oceana Gold(Au)OGC.AX
RELEASES NEW TECHNICAL REPORT FOR THE HAILE GOLD MINE
AU$ 2.46-5.38%Trend Power :
Western Areas NL(Au-Ni-Pl)WSA.AX
Advance Notice - Full Year Results Conference Call
AU$ 2.90-1.53%Trend Power :
Canadian Zinc(Ag-Au-Cu)CZN.TO
Reports Financial Results for Q2 and Provides Project Updates
CA$ 0.12+4.55%Trend Power :
Stornoway Diamond(Gems-Au-Ur)SWY.TO
Second Quarter Results
CA$ 0.02+100.00%Trend Power :
McEwen Mining(Cu-Le-Zn)MUX
TO ACQUIRE BLACK FOX FROM PRIMERO=C2=A0
US$ 0.97-2.02%Trend Power :
Rentech(Coal-Ngas)RTK
Rentech Announces Results for Second Quarter 2017
US$ 0.20-12.28%Trend Power :
KEFIKEFI.L
Reduced Funding Requirement
GBX 0.85+0.00%Trend Power :
Lupaka Gold Corp.LPK.V
Lupaka Gold Receives First Tranche Under Amended Invicta Financing Agreement
CA$ 0.04+0.00%Trend Power :
Imperial(Ag-Au-Cu)III.TO
Closes Bridge Loan Financing
CA$ 3.42+1.48%Trend Power :
Guyana Goldfields(Cu-Zn-Pa)GUY.TO
Reports Second Quarter 2017 Results and Maintains Production Guidance
CA$ 1.84+0.00%Trend Power :
Lundin Mining(Ag-Au-Cu)LUN.TO
d Share Capital and Voting Rights for Lundin Mining
CA$ 10.00-0.30%Trend Power :
Canarc Res.(Au)CCM.TO
Canarc Reports High Grade Gold in Surface Rock Samples at Fondaway Canyon, Nevada
CA$ 0.42-5.68%Trend Power :
Havilah(Cu-Le-Zn)HAV.AX
Q A April 2017 Quarterly Report
AU$ 0.17+0.00%Trend Power :
Uranium Res.(Ur)URRE
Commences Lithium Exploration Drilling at the Columbus Basin Project
US$ 6.80-2.86%Trend Power :
Platinum Group Metals(Au-Cu-Gems)PTM.TO
Platinum Group Metals Ltd. Operational and Strategic Process ...
CA$ 2.52-6.67%Trend Power :
Devon Energy(Ngas-Oil)DVN
Announces $340 Million of Non-Core Asset Sales
US$ 40.84-2.90%Trend Power :
Precision Drilling(Oil)PD-UN.TO
Announces 2017Second Quarter Financial Results
CA$ 8.66-0.35%Trend Power :
Terramin(Ag-Au-Cu)TZN.AX
2nd Quarter Report
AU$ 0.03+0.00%Trend Power :